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Abstract
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary dise-
ases. The impairment of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH),
adrenal hyperplasia, and excessive androgen synthesis. The syndrome is characterised by a considerable correlation between the genoty-
pe and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency.
The clinical manifestations of CAH in adults result from adrenocortical and adrenomedullary insufficiency, hyperandrogenism, and the
adverse effects of glucocorticosteroids used for the treatment of the condition. Non-classic CAH may sometimes be asymptomatic.
In patients with classic CAH obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia are more often seen than in the general
population. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction,
and cardiovascular disease. Long-term glucocorticosteroid treatment is also a known risk factor for osteoporosis.
Patients with CAH require constant monitoring of biochemical parameters (17a-hydroxyprogesterone [17-OHP] and androstenedione),
clinical parameters (body mass, waist circumference, blood pressure, glucose, and lipids), and bone mineral density by densitometry.
The principal goal of treatment in adults with CAH is to improve quality of life, ensure that they remain fertile, reduce the manifestations
of hyperandrogenisation in females, and minimise the adverse effects of glucocorticosteroid treatment.
Patients with classic CAH require treatment with glucocorticosteroids and, in cases of salt wasting, also with a mineralocorticosteroid.
Radical measures, such as bilateral adrenalectomy, are very rarely needed.
Asymptomatic patients with non-classic CAH require monitoring: treatment is not always necessary.
Medical care for patients with CAH should be provided by reference centres, as the management of such patients requires collaboration
between an endocrinologist, diabetologist, gynaecologist, andrologist, urologist, and psychologist.
(Pol J Endocrinol 2010; 61 (1): 142–155)
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Streszczenie
Wrodzony przerost nadnerczy (CAH, congenital adrenal hyperplasia) z niedoboru 21-hydroksylazy jest jedną z najczęstszych chorób dzie-
dziczonych w sposób autosomalny recesywny. Upośledzenie syntezy kortyzolu doprowadza do nadmiernej stymulacji nadnerczy przez
ACTH, przerostu nadnerczy i nadmiernej syntezy androgenów. Zespół ten cechuje się dużą korelacją pomiędzy genotypem i fenotypem
— rodzaj mutacji genu CYP21A2 wpływa na stopień niedoboru 21-hydroksylazy.
Objawy kliniczne w klasycznych postaciach CAH u dorosłych wynikają z: niedoczynności kory i rdzenia nadnerczy, hiperandrogenizmu
oraz działań ubocznych stosowanych w leczeniu glikokortykosteroidów. Postać nieklasyczna może czasem przebiegać bezobjawowo.
U pacjentów z klasyczną postacią CAH częściej niż w normalnej populacji stwierdza się otyłość, hiperinsulinizm i insulinooporność oraz
hiperleptynemię. Nieprawidłowości te sprzyjają rozwojowi zespołu metabolicznego i jego konsekwencjom, w tym dysfunkcji śródbłonka
i rozwojowi chorób sercowo-naczyniowych. Przewlekłe leczenie glikokortykosteroidami jest także znanym czynnikiem ryzyka rozwoju
osteoporozy.
Chorzy z CAH wymagają stałego monitorowania zarówno parametrów biochemicznych (17-OHP i androstendionu), jak i klinicznych
(kontrola masy ciała, pomiary obwodu talii, ciśnienia tętniczego, glikemii, lipidogramu) oraz densytometrycznej oceny gęstości mineral-
nej kości.
Podstawowym celem leczenia dorosłych chorych z CAH jest poprawa jakości życia, zapewnienie płodności, zmniejszenie objawów hiper-
androgenizacji u kobiet oraz minimalizacja objawów niepożądanych glikokortykosteroidoterapii.
Urszula Ambroziak M.D., Department of Internal Diseases and Endocrinology, Warsaw Medical University, Banacha St. 1a,
02–097 Warszawa, tel.: +48 22 599 28 77, mobil: +48 601 229 027, fax: +48 22 599 19 75, e-mail: umak@amwaw.edu.pl
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Pacjenci z postacią klasyczną wymagają leczenia glikokortykosteroidami, a w przypadkach przebiegających z utratą soli także mineralo-
kortykosteroidem. Niezwykle rzadko konieczne jest zastosowanie radykalnego postępowania, jakim jest obustronna adrenalektomia.
Pacjenci z postacią nieklasyczną, z brakiem objawów klinicznych wymagają obserwacji, leczenie natomiast nie zawsze jest konieczne.
Opieka nad dorosłymi chorymi z CAH powinna być prowadzona w ośrodkach referencyjnych, ponieważ wymaga współpracy endokry-
nologa, diabetologa, ginekologa, androloga, urologa i psychologa. (Endokrynol Pol 2010; 61 (1): 142–155)
Słowa kluczowe: wrodzony przerost nadnerczy, 21-hydroksylaza, glikokortykosteroidy
This paper has been financed by Medical University of Warsaw grant 1WN/W1/08
List of abbreviations
AA — Antiandrogens
ACTH — Adrenocorticotropic hormone
ART — Adrenal rest tumour
BMD — Bone mineral density
CAH — Congenital adrenal hyperplasia
GCS — Glucocorticosteroids
CRH — Corticotropin-releasing hormone
DHEA — Dehydroepiandrosterone
DHEAS — Dehydroepiandrosterone sulphate
DXA — Dual energy X-ray absorptiometry
DXM — Dexamethasone
EBM — Evidence-based medicine
GC/MS — Gas chromatography/mass spectrometry
3b-HSD2 — Type II 3b-hydroxysteroid dehydrogenase
11b-HSD2 — Type II 11b-hydroxysteroid dehydrogenase
GH — Growth hormone
IFG — Impaired fasting glucose
IGF-1 — Insulin-like growth factor-1
IGT — Impaired glucose tolerance
IMT — Intima-media thickness
LA GCS — Long-acting glucocorticosteroids
MCS — Mineralocorticosteroids
MRI — Magnetic resonance imaging
NC CAH — Non-classic congenital adrenal hyperplasia
OC — Oral contraceptives
17-OHP — 17a-hydroxyprogesterone
PCOS — Polycystic ovary syndrome
PRA — Plasma renin activity
SD — Standard deviation
SHBG — Sex hormone binding globulin
SV CAH — Simple virilising congenital adrenal hyperplasia
SW CAH — Salt-wasting congenital adrenal hyperplasia
THAldo — Tetrahydroaldosterone
Introduction
Congenital adrenal hyperplasia (CAH) belongs to a gro-
up of cortisol synthesis abnormalities inherited as an
autosomal recessive trait. The most common form of
CAH (accounting for 95% of the cases) is CAH due to
21-hydroxylase deficiency. Mutations of the CYP21A2
gene, which encodes for the enzyme 21-hydroxylase in
the zona fasciculata and zona glomerulosa of the adre-
nal cortex, result in cortisol deficiency and, if severe, in
aldosterone deficiency. This results in stimulation of
ACTH release and an excessive formation of these ste-
roids upstream of the blocked stage of synthesis, na-
mely 17a-hydroxyprogesterone (17-OHP), which un-
dergoes excessive conversion to androgens [1, 2]. Figu-
re 1 shows a diagram of adrenal and gonadal steroido-
genesis together with the abnormalities caused by
21-hydroxylase deficiency in CAH.
Three main types of CAH are distinguished depen-
ding on the severity of 21-hydroxylase deficiency:
— Classic salt-wasting CAH (SW CAH) — complete
lack of 21-hydroxylase activity in zona fasciculata
and zona glomerulosa of the adrenal cortex leading
to cortisol and aldosterone deficiency.
— Classic simple virilising CAH (SV CAH) — only
1–2% of 21-hydroxylase activity is preserved. Corti-
sol deficiency is present but no clinical manifesta-
tions of aldosterone deficiency are observed.
— Non-classic CAH (NC CAH) — late-onset adrenal
hyperplasia accompanied by a mild androgen excess
in late childhood or during puberty with 20–50% of
21-hydroxylase activity being preserved.
Based on neonatal screening available in such co-
untries as the United States, Portugal, the United King-
dom, Canada, or Spain, the mean prevalence of classic
CAH has been established at about 1 in 15,000 live bir-
ths. The prevalence is much higher in some ethnic gro-
ups, for instance, 1 in 280 among the Yupik Eskimos
inhabiting Alaska and 1 in 2100 among the inhabitants
of the French island Reunion. In Poland CAH is not inclu-
ded in any of the screening programmes and its prevalen-
ce is estimated at about 1 in 10,000 to 1 in 14,000 live births
[3]. Of the classic forms, SW CAH predominates in all the
assessed populations, accounting for 67% of cases [4].
Non-classic CAH is more common (about 1 in 1000
cases) [5]. As with classic CAH, here the prevalence in
certain ethnic groups is much higher, namely among
Ashkenazy Jews (1 in 27), Spaniards (1 in 40), and Cro-
ats (1 in 50) [6].
Clinical manifestations of congenital
adrenal hyperplasia in adults
The clinical manifestations of the classic forms of CAH
are very diverse and result from the varying degrees
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of: adrenocortical and adrenomedullary insufficiency,
androgen excess and individual sensitivity to andro-
gens, and the presence of ART and the adverse effects
of the glucocorticosteroids (GCS) used for the treatment
of this syndrome (Fig. 2).
Manifestations of adrenocortical
and adrenomedullary insufficiency
Adrenocortical insufficiency is diagnosed in patients with
classic CAH. Untreated or inadequately treated adult
patients with CAH may present with the following symp-
toms: general malaise, easy fatigability, loss of appetite,
and weight loss. Skin hyperpigmentation associated with
high levels of ACTH may also be present in some pa-
tients. When adrenal crisis is imminent, abdominal pain,
nausea, vomiting, diarrhoea, myalgia, low blood pressu-
re, and postural hypotension additionally develop [7].
Patients with classic CAH also present with adreno-
medullary insufficiency, which results from abnormal
formation of the adrenal medulla in the prenatal period
and from the disturbed synthesis of adrenomedullary
hormones leading, beeing in either case consequence of
cortisol deficiency. Patients with CAH have lower le-
vels of plasma adrenaline, methoxy adrenaline, and
urinary adrenaline compared to controls [8]. A reduced
adrenaline response to brief, intense physical exertion
has also been shown that fails to improve following
administration of stress doses of GCS [9]. Adrenaline
Figure 2. Components of the clinical picture of CAH
Rycina 2. Składowe obrazu klinicznego CAH
Figure 1. Pathway of adrenal and gonadal steroidogenesis in 21-hydroxylase deficiency. Modified by EM. Małunowicz from M. New
[3]; 21-DF — 21-deoxycortisol
Rycina 1. Schemat biosyntezy steroidów w nadnerczach i gonadach, pokazujący zmianę jej szlaku w CAH z niedoboru
21-hydroksylazy. Według M. New, w modyfikacji EM. Małunowicz [3]; 21-DF — 21-deoksykortyzol
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deficiency combined with cortisol deficiency increases
the risk of severe hypoglycaemia, especially in situations
of increased requirement for adrenal cortex hormones
[10]. Adrenaline deficiency that accompanies cortisol
and aldosterone deficiency and excessive levels of pro-
gesterone, which has antimineralocorticoid effects, is
also an additional risk factor for adrenal crisis in patients
with classic CAH unresponsive to increased doses of
GCS [1].
Reproductive system manifestations
The clinical picture in women with uncompensated
adrenal dysfunction is dominated by manifestations of
hyperandrogenism, such as hirsutism, acne, and men-
strual disorders. In women with classic CAH insufficient
development of the breasts is observed, which probably
results from excessive exposure to androgens in antenatal
life. About 40% of women with SW CAH and 20% of wo-
men with SV CAH suffer from fertility problems [11]. The
causes of reduced fertility are complex:
— intrauterine exposure of the foetus to high concentra-
tions of androgens may interfere with the development
of the hypothalamic-pituitary-gonadal axis [12];
— high levels of progesterone, 17-OHP, and androgens
adversely affect the dynamics of gonadotropin se-
cretion and cause anovulation cycles [10];
— high levels of progesterone may also suppress the
normal growth of endometrium and prevent the
implantation of an embryo [13];
— frequent co-existence of PCOS and insulin resistan-
ce increases the risk of anovulation cycles;
— presence of ART in the ovaries may contribute to
ovarian dysfunction [14];
— finally, fertility in women with classic CAH may be
reduced as a result of sex life problems arising from
abnormal anatomical structure of the external genitals
or suboptimal outcomes of repair surgery. This group
of women, more often than their healthy peers, re-
port pain and bleeding during sexual intercourse.
The main manifestations of CAH in adult men are
testicular adrenal rest tumour (ART) and infertility. The
causes of male infertility include:
— ART (see below),
— LH suppression,
— co-existence of insulin resistance and metabolic syn-
drome.
LH suppression results from excessive aromatisation
of androgens to estrogens, which leads to the suppres-
sion of gonadotropin release by the pituitary gland.
Hypogonadotropic hypogonadism seen in these pa-
tients may also be associated with reduced testicular
volume. It has, however, been shown that treatment
with GCS may improve the quality of semen and ferti-
lity in this group of men with CAH [15, 16].
Therefore, men with CAH should have their semen
tested at 3- to 5-year intervals, in addition to follow-up
imaging studies of the testes.
Adrenal rest tumour
Adrenal rest tumour (ART) is found in the vicinity of
the adrenal glands and along their embryonal pathway
of descent. Its most common localisations include the
coeliac plexus, broad ligament, testes (or ovaries in wo-
men), spermatic cord, kidneys, and other sites [14, 17].
The formation of ART is most frequently associated with
the embryonic period of adrenomedullary incorpora-
tion into the adrenal cortex or with the presence of
multiple adrenal anlagen [18]. ART is found in up to
50% of neonates and with time undergoes involution,
so that its prevalence in the general population of adults
is estimated at about 1%.
Testicular ART is present in at least a third of men
with classic CAH, being more prevalent in patients with
SW CAH. In one study, ultrasound scans revealed te-
sticular ART in as many as 16 out of 17 young men [19].
ART are found already in early childhood below 10 years
of age, even in adequately managed patients [20]. In
poorly controlled patients with heterotopic localisation
of adrenal cells, high ACTH levels may lead to testicular
tumours. Clinical manifestations include testicular ten-
derness and enlargement. In the majority of cases the-
se changes elude palpation. The diagnosis is made by
ultrasonography, which reveals hypoechoic, usually
bilateral foci that do not disturb the outlines of the te-
stes [19]. MRI may be utilised in the diagnostic workup
of testicular ART. The sensitivity of both imaging mo-
dalities in the diagnosis of ART is comparable [17].
ART in the testes may compress the seminiferous
canaliculi and vessels, which may result in fibrosis of
the parenchyma, potentially leading to abnormalities
of spermatogenesis, Leydig cell dysfunction, and infer-
tility. The discovery of focal changes in the testes may
be a source of concern, as it may suggest the presence
of a malignancy, such as malignant Leydig cell tumour.
In the majority of cases, ART decreases in size as a re-
sult of GCS treatment, which is an important differen-
tiating feature from Leydig cell tumour [21]. In equivo-
cal cases a biopsy of the suspect changes may be consi-
dered although, despite the typical histological featu-
res for Leydig cell tumours (Reincke’s crystals), the
diagnosis may still be considerably difficult to make [22].
Hence, in patients in whom the ART fails to decrease in
size following the administration of GSK, conservative
surgery should be considered [23]. As in patients with
oligospermia and pain, surgical treatment should be
considered in cases of GSC failure. The outcomes of such
treatment are good in terms of pain but uncertain in
terms of improved quality of semen [24].
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Manifestations of non-classic congenital
adrenal hyperplasia
Late-onset NC CAH accounts for about 1–2% of hype-
randrogenism syndromes in Caucasians [25, 26]. The
most common manifestations in adult women include:
hirsutism, oligomenorrhoea, acne, infertility, frontal
alopecia, and, rarely, primary amenorrhoea or manife-
stations of virilisation (male pattern hair growth, clito-
romegaly, deepening of the voice). Fertility disorders
affect about 13% of women with NC CAH [27]. The cau-
ses of infertility are complex and similar to those in the
classic forms of CAH. In some women the course of the
disease is asymptomatic, as confirmed in family studies
of patients diagnosed with NC CAH.
Although the incidence of NC CAH in men and
women is the same, few publications discuss the for-
mer, mainly because of the asymptomatic course of the
disease in this sex. In most men with NC CAH the func-
tion of Leydig cells is preserved and spermatogenesis
is normal, although some do exhibit ART and fertility
disorders [6].
Adrenal tumours
Focal changes in the adrenal glands, both unilateral and
bilateral, are definitely more prevalent in patients with
CAH, in both the classic and non-classic forms [28]. The
higher prevalence is also observed among heterozygo-
us patients (CYP21A2 gene mutation carriers) compa-
red to the healthy population [28]. Adrenal tumours in
CAH patients may decrease in size following treatment
with GCS. There are only isolated reports of adreno-
cortical carcinoma in patients with CAH [29, 30]. Pa-
tients suffering from CAH should therefore be exami-
ned for adrenal tumours, and patients with adrenal tu-
mours should be examined for CAH.
Height and bone mineral density
Adult patients with classic CAH are shorter than average
individuals in the general population by 1.4 SD (10 cm)
[31]. This results from the earlier exposure to androgens
and the accelerated growth rate in early childhood co-
upled with premature epiphyseal closure in the long
bones on the one hand and from the suppressive ef-
fects of excessive GSC doses on the secretion of growth
hormone on the other. Short stature may be a consequ-
ence of hyperandrogenism and transient hypercortiso-
laemia in childhood.
Long-term GCS treatment is a known risk factor for
reduced bone mineral density (BMD). While studies in
children have found no BMD decreases, studies in
adults have demonstrated significantly lower BMD in
patients with CAH versus controls [32–36] (Table I). The
group at highest risk of low BMD are patients with SW
CAH, who are managed with the highest doses of GCS.
Table I. BMD analysis in patients with CAH. Adapted from [10]
Tabela I. Analiza BMD u dorosłych chorych z CAH. Zmodyfikowano na podstawie [10]
Study Number of patients Country Results
Jaaskeleinen et al. 32 patients (30 with Finland BMD (LS, FN) lower than in CG
classic CAH, 16 women, Negative correlation
aged 16–52 years) v.  of BMD and GCS dose
Finnish population LA GCS — lower BMD
King et al. 26 female patients USA Osteopaenia:
with classic CAH (21–71 45% SW, 13% SV, 11% CG
years old) v. 9 CG BMD (LS, WB) lower than
in CG (p < 0.05)
patients with osteopenia
— reduced DHEA and DHEAS
(mainly in postmenopausal women)
Sciannamblo et al. 30 patients with classic CAH Italy BMD WB lower than in CG (p < 0.03)
(15 women, 16–29 years old) v. 138 CG Bone fraction ALP and
C-telopeptide higher in CAH (p < 0.04)
No correlation between BMD
or bone turnover markers and the
dose of GCS
Falhammar et al. 61 females (55 with classic CAH, Sweden BMD (LS, FN, WB) lower
18–63 years old) v.  61 CG  than in CG (p < 0.001)
< 30 years osteopaenia 48% v. 12% CG
> 30 years osteopaenia 73% v. 21% CG
Osteoporotic fractures more often
in CAH (p = 0.058)
LS — lumbar spine, FN — femoral neck, CG — control group, WB — whole body
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It has also been shown that lower BMD values are fo-
und in patients managed with longer-acting GCS com-
pared with those managed with hydrocortisone [34].
Moreover, osteopaenic patients have exhibited reduced
levels of androgens: dehydroepiandrosterone (DHEA)
and dehydroepiandrosterone sulphate (DHEAS), which
was particularly the case with postmenopausal women
managed with long-acting GCS [35]. A Swedish study
by Falhammar et al. attracted particular interest, as it
followed up a subgroup of patients over 30 years of age.
Signs of osteopaenia were found in 73% of women with
classic CAH versus 21% of control patients. The study
was also the first study to have pointed to the incre-
ased tendency for osteoporotic fractures (spine, femo-
ral neck, and wrist fractures) in patients managed with
GCS [36].
Indications for the determination of bone turnover
markers in patients with CAH have not been defined.
To summarise the findings of the above studies, se-
veral causes of reduced BMD in adult patients with CAH
may be identified:
— long-term treatment with GCS;
— the use of longer-acting GCS exhibiting a greater
ACTH-suppressing potential and hence a greater
androgen-suppressing potential;
— the use of higher doses of GCS;
— co-existence of other risk factors for osteoporosis, e.g.
hypogonadism.
These findings point to the necessity of constant
monitoring of the bones and osteoporosis prevention.
The use of the lowest possible doses of GCS, avoidance
of long-acting GCS in peri- and postmenopausal wo-
men, and detailed monitoring of other factors contri-
buting to the development of osteoporosis should be
the first step towards the prevention of bone mass loss
in patients with CAH. A diet high in calcium and vita-
min D, calcium and vitamin D supplementation, and
appropriate physical activity are further basic recom-
mendations for these patients. A periodic bone densi-
tometry in adults with CAH is also recommended.
Metabolic syndrome
Classic CAH is a considerable risk factor for metabolic
syndrome, as patients with these variants of the dise-
ase exhibit increased body fat, increased incidence of
overweight/obesity, higher insulin levels, and insulin
resistance [37, 38].
The main causes of metabolic abnormalities in pa-
tients with CAH are periodic hypercortisolaemia (which
cannot be avoided during GCS treatment), insufficien-
cy of the adrenal medulla, and hyperandrogenism
(Fig. 3) [8].
Following a single oral dose of hydrocortisone, the
peak serum concentration is achieved within 1–2 hours
with the drug having been completely cleared from the
serum within 5–6 hours [39]. Patients with CAH are the-
refore at risk of constant or periodic hypocortisolaemia
coupled with stimulation of the adrenal cortex by
ACTH, or of transient hypercortisolaemia.
The adrenomedullary insufficiency occurring in
patients with classic CAH carries with it some impor-
tant metabolic implications:
— adrenaline deficiency is one of the factors promoting
hyperinsulinaemia and insulin resistance as
a result of the absence of inhibition receptor b3-me-
diated catecholamine effects on insulin secretion [40];
— in the same mechanism, adrenaline deficiency pro-
motes hyperleptinaemia [40];
Figure 3. Metabolic associations in patients with classic CAH. Adapted from [73]
Rycina 3. Zależności metaboliczne u chorych z klasyczną formą CAH. Zmodyfikowano na podstawie [73]
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— adrenaline deficiency promotes obesity. Activation
of the sympathetic nervous system increases lipoly-
sis, reduces storage of triglyceride-rich lipoproteins
in the adipose tissue, and increases thermogenesis
in the brown adipose tissue. All this depletes the fat
stores. In adrenaline deficiency, thermogenesis and
lipolysis are impaired contributing to increased body
fat [40].
Hyperandrogenism is another factor that decreases
insulin sensitivity and leads to hyperinsulinaemia most
likely resulting from the stimulation of secretion of
growth hormone (GH) and insulin-like growth factor 1
(IGF-1).
Hyperinsulinaemia and insulin resistance coupled
with obesity and periodic hypercortisolaemia may all
promote the development of hypertension, dyslipida-
emia, abnormalities of carbohydrate metabolism, and
direct endothelial injury, increasing cardiovascular risk
in patients with CAH. One study showed an absence
of the nocturnal dip in systolic blood pressure in 84%
of patients with classic CAH, which is considered a si-
gnificant cardiovascular risk factor [41]. Nineteen pa-
tients with classic CAH and a mean age of 28.5 years
exhibited, in addition to reduced insulin sensitivity, an
increased intima-media thickness (IMT) versus controls,
which is an early indicator of atherosclerosis and ano-
ther important cardiovascular risk factor [42].
Normalisation of blood pressure and modification
of metabolic abnormalities are known to slow down the
progression of atherosclerotic changes significantly.
Patients with classic CAH should therefore be carefully
monitored for metabolic syndrome elements. Early li-
festyle intervention, consisting mainly of appropriate
diet and exercise, may reduce cardiovascular risk in this
group of patients.
Psychosocial problems and quality of life
A recent study evaluating quality of life in patients with
CAH carried out at 17 centres in the UK followed up
203 patients (65 men and 138 women aged 18–69 years)
and demonstrated, in contrast to previous observations,
that the quality of life in patients with CAH was signifi-
cantly reduced compared to the quality of life in pa-
tients with congestive heart failure and patients on ha-
emodialysis [43].
Psychosocial problems in women with CAH are an
important issue. They result from the effects of andro-
gens on the CNS functions (in the pre- and postnatal
period) on the one hand and from the somatic conse-
quences of hyperandrogenisation on the other [44].
Female patients with CAH are more frequently lonely,
are less sexually active, and have an inferior body ima-
ge and an inferior perception of themselves in the gro-
up [45]. Homosexual and bisexual behaviour is also
more prevalent among women with classic and non-
classic CAH.
When cognitive function was evaluated in patients
with CAH their IQ values were not found to differ signi-
ficantly from those in the control group [46]. Only pa-
tients with SW CAH who underwent adrenal crises and
were exposed to hypoglycaemia or electrolyte imbalan-
ce in their childhood may present lower IQ values [47].
Diagnostic evaluation of congenital
adrenal hyperplasia
Diagnostic evaluation of the classic
forms of congenital adrenal hyperplasia
The classic form of CAH (SW CAH), due to its clinical
signs and symptoms of salt loss in both sexes (additio-
nally accompanied in girls by abnormal external geni-
talia), is detected, in the majority of cases, in the neona-
tal period. On the other hand, SV CAH in boys and in
girls with a mild clitoromegaly may not be diagnosed
until early childhood when signs of precocious puber-
ty develop. Mild clinical forms of SV CAH are someti-
mes not diagnosed until adulthood.
The laboratory diagnosis of classic CAH is based on
the following:
— determination of serum levels of 17-OHP,
— ACTH stimulation test,
— urinary steroid profile by gas chromatography/mass
spectrometry (GC-MS),
— testing for CYP21A2 gene mutations.
The screening test for CAH due to 21-hydroxylase
deficiency involves the determination of 17-OHP in
a blood drop collected on a filter paper 3–5 days after
birth.
Neonatal screening in many European countries and
many states in the US enables early detection of CAH
due to 21-hydroxylase deficiency.
In most patients with SW CAH or SV CAH, the se-
rum levels of 17-OHP exceed 100 ng/ml (with the nor-
mal values equalling < 1–2 ng/ml, depending on age,
sex, and test kit) [48].
Because of the risk of false positive results (preterm
babies, birth weight below 2500 g, distressed neonates)
all the elevated 17-OHP results require verification by
the methods mentioned above (bullets 2–4) [49].
Basing the diagnosis merely on 17-OHP determina-
tions in the serum may also be the reason for misdia-
gnosing 21-hydroxylase deficiency, as it should be bor-
ne in mind that elevated levels of 17-OHP are also fo-
und in other abnormalities of steroidogenesis, such as:
— CAH due to 11b-hydroxylase deficiency,
— CAH due to type 2 3b-hydroxysteroid dehydroge-
nase (3b-HSD2) deficiency,
— 17,20-lyase deficiency with normal cortisol levels,
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— reduced sensitivity of the glucocorticosteroid receptor,
— CAH due to the deficiency of P450 oxidoreductase,
which is a cofactor of 21-hydroxylase, 17a-hydroxy-
lase, and aromatase.
In addition, elevated 17-OHP levels are also obse-
rved in preterm babies and newborns with birth we-
ight below 2500 g. This results from cross-reactions be-
tween the antibodies used in the 17-OHP assays and
steroids of the still very active foetal layer of the adre-
nal cortex.
Neonates born at term during distress (stress stimu-
lation of the adrenal cortex by ACTH) also secrete in-
creased amounts of 17-OHP [50].
The ACTH stimulation test measuring 17-OHP fol-
lowing the administration of synthetic adrenocortico-
tropic hormone is used in diagnostically ambiguous
cases and for the differentiation between classic and
non-classic CAH [50, 51]. Tetracosactide (Synacthen) at
a dose of 250 µg is given via intramuscular injection,
and serum 17-OHP concentrations are determined at
baseline and at 30 and 60 minutes after dosing, altho-
ugh some centres prefer to determine 17-OHP at two
time points: at baseline and at 60 minutes [17]. The post-
stimulation levels of 17-OHP are generally highest in
SW CAH (300–1000 ng/ml), intermediate in SV CAH
(100–300 ng/ml), and lowest in NC CAH (15–100 ng/ml).
Urine steroid profiling by GC/MS enables a precise
assessment of steroidogenesis abnormalities. A single
portion of urine suffices to establish the diagnosis of
CAH due to 21-hydroxylase, 11b-hydroxylase, 17a-hy-
droxylase, or 3b-HSD deficiency. The diagnosis of other
steroidogenesis disorders associated with the signs and
symptoms similar to CAH due to 21-hydroxylase defi-
ciency requires a 24-hour urine collection [50, 52].
Although 21-deoxycortisol is the marker typical of
21-hydroxylase deficiency of purely adrenal origin, no
commercial assays for determining its serum levels are
available. Pregnanetriolone, determined in the steroid
profile by GC/MS, is the metabolite of this steroid.
Patients with SW CAH have reduced blood levels
of aldosterone and 11-deoxycorticosterone and eleva-
ted plasma renin activity (PRA), hypernatraemia, hy-
perkalaemia, and metabolic acidosis [49].
Recent studies have shown that a mild aldosterone
deficiency is also present in SV CAH and NC CAH, al-
though it is not accompanied by biochemical signs of
salt wasting. These patients have an abnormal (reduced)
ratio of serum aldosterone to PRA. The increased PRA
stimulates the mildly disrupted aldosterone synthesis to
a level that ensures normal sodium concentrations, which
is why the aldosterone–PRA ratio may be used to assess
aldosterone synthesis in patients with various forms of
CAH due to 21-hydroxylase deficiency [53].
Genetic testing with the assessment for CYP21A2
mutation enables diagnosis in 90–95% of patients.
Diagnostic evaluation of non-classic
congenital adrenal hyperplasia
The diagnostic evaluation of NC CAH involves:
— Determination of serum 17-OHP,
— ACTH stimulation test,
— Urinary steroid profiling,
— Genetic testing for CYP21A2 mutations.
The diagnosis of NC CAH is most commonly based
on the determination of baseline 17-OHP levels and the
ACTH stimulation test. Unfortunately, the reference
values of 17-OHP prior to and following stimulation are
not unequivocally established. Due to the circadian rhy-
thm of 17-OHP secretion (parallel to that of cortisol) and
its adrenal (10%) and gonadal (90%) origin, it is recom-
mended that the diagnostic evaluation in menstruating
women should be performed in the follicular phase (be-
tween days 7 and 9 of the cycle) in the early morning
hours. The following interpretation of results is curren-
tly proposed [54, 55]:
— 17-OHP levels in the follicular phase below 2.0 ng/ml
(or below 1.7 ng/ml, as preferred by other authors)
rules out the diagnosis of NC CAH with a high like-
lihood;
— 17-OHP levels between 1.7 and 2.0 ng/ml are an in-
dication for the ACTH stimulation test;
— 17-OHP levels exceeding 4.0 ng/ml are highly sug-
gestive of NC CAH and an indication for the ACTH
stimulation test;
— 17-OHP levels exceeding 10.0 ng/ml in the follicular
phase confirm the diagnosis of CAH.
The ACTH stimulation test is frequently decisive in
the diagnostics of NC CAH. The 17-OHP concentrations
following ACTH stimulation that are typical of NC CAH
are most commonly in the range of 15–100 ng/ml [51].
Most authors consider 17-OHP levels ≥ 10 ng/ml the
lowest cutoff value for the diagnosis of NC CAH [55]
although asymptomatic carriers (heterozygotes) may
also fall between the values of 10 and 15 ng/ml. As in
the classic forms of CAH, urinary steroid profiling by
GC/MS (where metabolites of 17-OHP, 21-deoxycorti-
sol, cortisol, and androstenedione are simultaneously
determined) and genetic testing for CYP21A2 mutations
may prove helpful in establishing the diagnosis.
Molecular studies have identified a separate geno-
type of NC CAH compared to the classic forms. Patients
may carry two mild mutations on both alleles (most
commonly V281L and P30L) or have combined hetero-
zygotes with a mild mutation on one allele and a seve-
re mutation on the other, typical of SW CAH and SV
CAH [6].
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Female patients with NC CAH have an increased
24-hour excretion of the aldosterone metabolite tetra-
hydroaldosterone (THAldo), which — similarly to pa-
tients with SV CAH — reflects the stimulation of aldo-
sterone formation by renin to compensate for the mild
aldosterone deficiency [56].
Management of congenital
adrenal hyperplasia
The management of CAH depends on the age of onset,
sex, and the severity of enzyme deficiency. The princi-
pal goals of treatment in patients with classic CAH is to
improve the quality of life, to correct glucocorticostero-
id and mineralocorticosteroid deficiency and to reduce
the signs of hyperandrogenism in girls/women. Treat-
ment often improves fertility in both sexes. There is no
consensus as to the management of CAH that would
comply with the principles of evidence-based medici-
ne (EBM). In addition, the widely varied clinical pictu-
re of patients with CAH compels an individual appro-
ach to patient management.
Glucocorticosteroids
Patients with the classic forms of CAH, both SW CAH
and SV CAH, require treatment with glucocorticoste-
roids and, in the case of SW CAH, with fludrocortisone.
Glucocorticosteroid treatment of patients with CAH
is very difficult. The substitutive doses of GCS are suffi-
cient to manage adrenocortical insufficiency but in the
majority of cases fail to provide sufficient suppression
of ACTH secretion or to prevent hyperandrogenism.
On the other hand, supraphysiologic doses of GCS ef-
fectively suppress ACTH secretion and reduce andro-
gen levels but are associated with adverse effects. Fin-
ding “the golden mean” for each particular patient is
therefore quite a challenging task (Fig. 4).
While in children hydrocortisone 3–4 times daily is
the basic GCS, in adults the administration of longer-
-acting GCS given once or twice daily is more common-
ly recommended [10]. The GCSs used in adults include:
prednisone 5.0–7.5 mg/day, prednisolone 5–10 mg/day,
dexamethasone (DXM) 0.25–0.50 mg/day, hydrocorti-
sone 15–45 mg/day, or a combination of several GCSs. Flu-
drocortisone in adults is usually used at a dose of 50–100–
–200 µg/day. A reduction in the sensitivity to sodium loss
is observed with age, so that salt replenishment is no longer
required in adults as it is in children and treatment with
increasingly lower doses of fludrocortisone is possible [1].
Unfortunately, there is no single dose equivalent for speci-
fic glucocorticosteroids. The most commonly cited one is
1 mg of dexamethasone = 16 mg of prednisone = 80 mg
of hydrocortisone [57]. According to other sources, the equ-
ipotent doses are 1 mg of dexamethasone = 7 mg of pred-
nisone = 27 mg of hydrocortisone [58]. Individual sensi-
tivity to GCS (especially DXM) is very important here.
The dose should always be selected on an individual ba-
sis, carefully observing the patient, monitoring for side
effects, and evaluating endocrine parameters (see below).
No randomised clinical studies have been perfor-
med to assess the various glucocorticosteroid formula-
tions and the various glucocorticosteroid regimens. Pre-
ferences for the individual formulations vary between
centres. Among the patients managed at Middlesex
Hospital in London, patients with SW CAH have most
commonly received prednisolone (53%), followed by
hydrocortisone (37%), dexamethasone (4%), and com-
binations of various GCSs (5%). All patients have also
received fludrocortisone at doses of 50–400 µg. Patients
with SV CAH have received hydrocortisone (42%), pred-
nisolone (31%), dexamethasone (3%), and combinations
of various GCSs (12%), while 12% remained without tre-
atment. In this group of patients 38% have also received
fludrocortisone [13]. In most adult cases, in order to pre-
vent the morning ACTH and 17-OHP peaks, the only or
the highest GCS dose is used in the evening.
Treatment in NC CAH is only indicated in sympto-
matic cases. Glucocorticoid treatment in women may
be considered if hyperandrogenism, menstruation di-
sorders, or infertility is present. Irregular menses and
acne usually subside within about 3 months of treat-
ment with GCS, while hirsutism does not resolve until
about 30 months of treatment [6]. This is why female
patients with NC CAH receive antiandrogens in addi-
tion to or instead of GCS, and oral contraceptives.
In order to induce ovulation, if GCS fail, clomifene
citrate is most commonly used [11].
Adult men with NC CAH require GCS treatment
only if ART and/or oligospermia are present.
Although primary adrenocortical insufficiency is not
observed in patients with NC CAH, patients on long-
term glucocorticoid treatment may develop secondary
adrenocortical insufficiency. Hence, in distressing situ-
ations (infection, surgery), they should be receiving
appropriately increased doses of GCS.
Figure 4. Difficulties in the management of CAH patients [10]
Rycina 4. Trudności w leczeniu CAH. Zmodyfikowano na
podstawie [10]
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In women with CAH, both classic and non-classic,
who are planning to become pregnant, DXM should
not be used (see below).
Bilateral adrenalectomy
Bilateral adrenalectomy is a rarely used procedure with
limited indications. The principal indication is drug-re-
sistant hyperandrogenism, in which case adrenalecto-
my allows the use of lower doses of GCS aimed only at
replenishing the hormone deficiency. A five-year stu-
dy investigated 18 patients with CAH who had un-
dergone bilateral adrenalectomy. Hyperandrogenism re-
solved, but the patients still required relatively high do-
ses of GSC (equivalent to hydrocortisone 11 mg/m2/day)
to prevent hyperpigmentation and ART [59]. Another
potential indication may be to maintain high progeste-
rone levels in the follicular phase that are not suppres-
sed by GCS treatment. This leads to ovulation abnorma-
lities on the one hand and to endometrial atrophy and
implantation abnormalities on the other. Bilateral adre-
nalectomy performed in two female patients resulted in
normalisation of progesterone levels and becoming pre-
gnant [13].  However, such treatment should be limited
to special situations due to the risk of the surgery itself
and the high changes of development of ART.
Reconstructive treatment
In girls with classic CAH, plastic surgery of the external
genitals is an equally important element of management
as drug treatment. The methods of reconstructive surge-
ry in many female patients qualified for the treatment vary
with the country. The expertise of centres specialising in
the treatment of this type of anomalies enables constant
progress and improvement of surgical techniques. For se-
veral years now, surgery has been indicated in female
neonates with CAH [49]. It is less and less common that
plastic surgery of the genitals needs to be repeated in adult
age, which only 10–15 years ago was commonplace [60].
The following are considered the criteria of success-
ful reconstructive surgery [2]:
— urinary continence,
— free outflow of menstrual blood,
— possibility of easily inserting safety tampons,
— possibility of full vaginal penetration during sexual
intercourse,
— possibility of achieving expected sexual satisfaction,
— good cosmetic effect.
Treatment of hyperandrogenism syndrome
Some women with classic and non-classic CAH require
treatment with oral contraceptives with the aim of re-
gulating the menstrual cycle and preventing changes
in the ovaries typical of PCOS. Similarly, in cases of se-
vere signs of hyperandrogenisation, such as hirsutism
and acne, oral contraceptives and antiandrogens (cy-
proterone acetate, spironolactone) may be helpful [2].
The effectiveness of both therapies, especially in terms
of managing hirsutism, is considered superior to GCS
[61]. Oral contraceptives increase the synthesis of sex
hormone binding globulin (SHBG) in the liver, incre-
asing its blood levels, reducing free androgen levels,
blocking androgen receptors, and suppressing both
ovarian and adrenal androgens through effects on
ACTH, which is why, in addition to regulating the men-
strual cycle, they are also employed in the treatment of
hirsutism in female patients with CAH.
Flutamide is also used in the treatment of severe
hyperandrogenisation (androgen receptor blocking) as
well as finasteride (inhibition of 5a-reductase) [62, 63].
Novel treatments
Current studies investigating novel treatments for
adults with CAH focus on the use of CRH receptor an-
tagonists and gene therapy.
The CRH receptor antagonist antalarmin is a CRH-1
receptor antagonist. By binding with the target recep-
tor, antalarmin blocks the binding of the natural CRH
ligand, thereby suppressing ACTH secretion in another
mechanism than GCS does [64]. Preliminary results of
animal studies are promising, but the drug is still in the
investigative phase.
Gene therapy as a potential method of radical treat-
ment for CAH patients is still in the experimental pha-
se. It is difficult to tell when the method will be found
useful in clinical practice.
Treatment during pregnancy
Dexamethasone is a steroid that is not a substrate for
placental 11b-hydroxysteroid dehydrogenase 2 (11bHSD2),
thanks to which it passes through the placenta to the
foetus. The only indication for using dexamethasone
during pregnancy is prenatal management of a female
foetus at risk of classic CAH. The criteria to be met befo-
re considering prenatal treatment in carriers (heterozy-
gotes) are as follows [2, 49]:
— presence of siblings with a mutation causing classic
CAH confirmed by DNA testing,
— determination of the parents’ (heterozygotes’) ge-
notypes in terms of CYP21A2 mutations,
— possibility of rapid DNA analysis for CYP21A2 mu-
tations in the foetus,
— possibility of initiating treatment less than 9 weeks
since the last menstrual period,
— parents’ decision to keep the pregnancy,
— compliance on the part of the parents.
Dexamethasone must be initiated at 6 weeks of ge-
station (preferably right after the pregnancy has been
confirmed) because its aim is to eliminate virilisation of
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the genitals of the female foetus. The genetic evaluation
of the material obtained during trophoblast biopsy and
amniocentesis is not possible before 9–11 and 15–18
weeks of gestation, respectively [65–67], which is why
during the first phase of treatment or before the gene-
tic testing results have come back some of the foetuses
receive treatment unnecessarily. In spite of the confir-
med efficacy of prenatal management of CAH in terms
of achieving normal structure of the external genitals
in girls, there is no consensus as to the safety of DXM
for both the mother and the child [1, 49, 65, 68, 69]. Such
treatment should therefore be regarded as a medical
experiment, as its remote consequences are presently
unknown. The unnecessary treatment of most foetuses
(female foetuses without CYP21A2 mutations, male fo-
etuses with or without CYP21A2 mutations) is an ethi-
cal problem. Treatment may be conducted in speciali-
sed centres, after approval of the relevant ethics com-
mittees has been granted and after the mother to be
given dexamethasone has signed a written informed
consent form. Specialist maternal monitoring, followed
by long-term monitoring of the babies is necessary du-
ring the treatment. A diagram of prenatal management
is presented in Figure 5.
During pregnancy, women with CAH should rece-
ive a GCS that does not penetrate the placenta (hydro-
cortisone, prednisone, prednisolone). Hydrocortisone
is the preferred drug in most centres. DXM may only
be used in prenatal therapy [49]. The dosage of GCS
and monitoring of treatment is the same as in non-pre-
gnant women, although some authors prefer to moni-
tor the levels of testosterone, which should not exceed
2 ng/ml in this period. Elevated androgen levels in pre-
gnant women with CAH do not result in virilisation of
healthy female foetuses because of the activity of pla-
cental aromatase, high SHBG levels, and the anti-an-
drogenic effects of high progesterone levels [1]. The
baby should be delivered at a reference centre, with elec-
tive caesarean section being the only delivery option in
women with a history of plastic surgery of the genitals
[2]. In the perinatal period the mother should receive
increased doses of GCS, as in distressing situations.
The use of GCS and mineralocorticoids by mothers
with CAH is not a contraindication for breastfeeding,
although both GCS and MCS are excreted to human
milk. The levels of DXM and fludrocortisone in human
milk have not been established.
Women with NC CAH who did not receive GCS
before pregnancy do not require treatment with GCS
during pregnancy. Women who did receive GCS after
becoming pregnant require continuation of treatment
with a GCS that does not penetrate the placenta, at sub-
stitutive doses, according to the generally accepted prin-
ciples of management in secondary adrenocortical in-
sufficiency.
Genetic testing and genetic counselling
The development of molecular diagnostics in CAH and
the availability of prenatal treatment have made it ne-
cessary to provide the patients — potential parents
— with as much information about the risk of CAH in
their offspring and treatment options as possible. An eva-
luation of the risk of giving birth to a girl with classic
CAH in several clinical situations is presented in Table II.
Monitoring of treatment
While the principal goal of paediatric care is to monitor
the correct physical development and the correct sexu-
al maturation of the patients, the management in adults
should be focused on avoiding complications of long-
term steroid treatment. The management strategy sho-
uld take into consideration the selection of the lowest
effective dose of GCS, as assessed by clinical and bio-
chemical parameters.
No GCS treatment monitoring standards for adult
patients with CAH due to 21-hydroxylase deficiency
have been established so far.
The clinical parameters that need to be monitored
include: the presence of Cushingoid manifestations;
body weight and body fat; waist circumference; blood
pressure; bone mineral density; and periodic ultraso-
und scan of the testicles and examination of the semen
in men. The principal biochemical parameters used to
monitor GCS treatment include 17-OHP, androstene-
dione, and testosterone.
Figure 5. Diagram of prenatal management of CAH with
dexamethasone
Rycina 5. Schemat leczenia prenatalnego CAH deksametazonem
153
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 61 (1)
SZ
K
O
LE
N
IE
PO
D
Y
PL
O
M
O
W
E
Suppression of 17-OHP to normal limits for healthy
individuals should be avoided because it would invo-
lve the use of GCS doses resulting in adverse effects.
An optimal dose of GCS should maintain androgens
within normal ranges and 17-OHP (within the range of
4–12 ng/ml) [70]. However, achieving target 17-OHP
values should be individualised. In young women try-
ing to become pregnant, 17-OHP levels should not exce-
ed 8–10 ng/ml, while the concentration of the hormone
in adult men without signs of testicular ART should be
kept below 25 ng/ml [10].
Monitoring of treatment with
mineralocorticosteroids
PRA is the basic biochemical parameter used in the
monitoring of fludrocortisone treatment. As there is no
consensus as to the conditions in which PRA should be
tested, determination of the parameter after 2 hours of
remaining in the vertical position (sitting, standing, or
while walking) seems the most appropriate. It is recom-
mended that the screening PRA values should be wi-
thin normal or slightly above normal range (up to 2 ti-
mes the upper limit of norm) [13]. Excessive PRA sup-
pression is suggestive of mineralocorticosteroid over-
dose. Excessively high values of PRA correlate with
elevated angiotensin II, which is known to stimulate
the initial stages of adrenal steroidogenesis on the one
hand and to be a cardiovascular risk factor on the other
[71, 72]. Sodium and potassium are two other bioche-
mical parameters that reflect water and electrolyte ba-
lance in patients on mineralocorticosteroids, although
these parameters are less reliable in older children and
adults. The clinical parameters that require monitoring
include oedema and blood pressure.
The proposed management algorithm for adult pa-
tients with CAH is presented in Figure 6.
Figure 6. Management of patients with classic and non-classic CAH. Adapted from [10].
Rycina 6. Schemat postępowania u chorych z klasyczną i nieklasyczną postacią CAH. Zmodyfikowano na podstawie [10]
*Long-acting GCS should not be the drugs of choice in elderly patients. #Stress dose of GCS in cases of long-term GCS use
Table II. Assessment of the risk of giving birth to a girl with classic CAH in selected clinical situations
Tabela II. Ocena ryzyka urodzenia dziewczynki z klasyczną formą CAH w wybranych sytuacjach klinicznych
Clinical situation Chances of giving birth to a girl with classic CAH
One child with classic CAH 1/8
One partner with classic CAH, 0.4% or 1/250
unknown genetic status of the other partner [1 parent 2 classic alleles] × [1.6% carriers with classic mutation]
× [1/2 chance that the carrier will pass on the allele to the child]
× [1/2 chance that the foetus is female]
One partner with non-classic CAH, unknown 0.1% or 1/1000
genetic status of the other partner [50% carriers with classic mutation]
(50% compound heterozygotes) × [1.6% carriers with classic mutation in the general population]
× [1/4 chance that both classic alleles will be passed onto the offspring]
× [1/2 chance that the foetus is female]
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Summary
While the goals and principles of management in chil-
dren have been well described in the past fifty years,
the management of adults with CAH is mostly based
on experiences gained in small and relatively young
patient groups. EBM-based standards are still lacking.
However, preliminary observations allow the identifi-
cation of the tasks to be addressed in the care for an
adult patient with CAH:
— to establish the treatment goals,
— to establish further management with GCS,
— to minimise and monitor for adverse effects of GCS,
— to improve sexual function,
— to improve fertility,
— to provide psychological support,
— to prevent osteopaenia,
— to prevent metabolic syndrome and limit cardiova-
scular risk.
These tasks should be carried out at reference cen-
tres in collaboration with a number of specialists, inc-
luding endocrinologists, gynaecologists, urologists,
dieticians, sexologists, geneticists, and psychologists,
which should lead to optimal outcomes in adult pa-
tients with CAH.
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